bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, provides clinical applications that facilitate improved industrial microbiological control and minimize the risks of contamination of pharmaceuticals, cosmetics, and food products throughout the production value chain. The company offers in vitro diagnostic solutions for the diagnosis of infectious diseases, antimicrobial resistance, and healthcare-associated infections and for use in cardiovascular emergencies, and various cancers, and for application in the fields of agri-food, biopharma, and cosmetics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

bioMerieux's R&D arm focuses on innovation as a key component of its strategy to enhance public health. The company's R&D initiatives are aimed at translating external health trends and new technologies into strategic R&D projects. The company operates 18 R&D centers employing around 1,800 scientists with diverse expertise. bioMerieux's open innovation model is based on internal innovation programs, strategic acquisitions, international collaborations, joint research laboratories, scientific and technology watch, and exploring new applications for diagnostics solutions. The company is committed to enhancing in vitro diagnostics capabilities to address major health challenges globally. The R&D Department at bioMerieux plays a crucial role in informing the company's strategy and impacting its business. It manages development projects in areas such as molecular biology, microbiology, immunoassays, information technology, data analysis, and sequencing. The department includes Clinical and Regulatory Affairs, which is involved in devising development and registration strategies for systems and products. The R&D Department also incorporates an eco-design approach into projects and works closely with Customer Service to maintain product performance throughout their life cycle. The company has formed significant technology alliances, including partnerships with Oxford Nanopore Technologies, the MILA Institute, Washington University, and several European and French collaborative projects. As of December 31, 2025, the company has 18 R&D centers across different regions: 6 in America, 9 in Europe, Middle East, and Africa, and 4 in Asia Pacific. Logistics are organized around global and regional platforms for storage and shipping, with sites in the US, Singapore, and France. In FY2025, bioMerieux spent EUR507.4 million on its R&D activities, which as a percentage of revenue, stood at 12.5% and grew 3.2% YoY. As of December 31, 2025, the company’s patent portfolio comprised 466 patent families of which 454 patents were granted in the US and 300 in Europe. In addition, the company owns 297 trademark families and 723 registered domain names.